Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
20014.3k citationsEdmund J. Lewis, Lawrence G. Hunsicker et al.New England Journal of Medicineprofile →
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
20132.5k citationsBenjamin M. Scirica, Deepak L. Bhatt et al.New England Journal of Medicineprofile →
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
20181.9k citationsThomas A. Zelniker, Stephen D. Wiviott et al.profile →
Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ
1990590 citationsItamar Raz, Clifton Bogardus et al.profile →
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
2014545 citationsBenjamin M. Scirica, Eugene Braunwald et al.Circulationprofile →
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus
2019534 citationsThomas A. Zelniker, Stephen D. Wiviott et al.Circulationprofile →
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
2020313 citationsThomas A. Zelniker, Marc P. Bonaca et al.Circulationprofile →
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
2017275 citationsLawrence A. Leiter, Itamar Raz et al.profile →
Overview of oxidative stress and inflammation in diabetes
202466 citationsItamar Raz et al.Journal of Diabetesprofile →
Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations
202444 citationsGiorgio Melloni, Benjamin M. Scirica et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Itamar Raz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Itamar Raz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Itamar Raz more than expected).
This network shows the impact of papers produced by Itamar Raz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Itamar Raz. The network helps show where Itamar Raz may publish in the future.
Co-authorship network of co-authors of Itamar Raz
This figure shows the co-authorship network connecting the top 25 collaborators of Itamar Raz.
A scholar is included among the top collaborators of Itamar Raz based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Itamar Raz. Itamar Raz is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Raz, Itamar, et al.. (2024). Overview of oxidative stress and inflammation in diabetes. Journal of Diabetes. 16(10). e70014–e70014.66 indexed citations breakdown →
Aoki, Yasunori, Bengt Hamrén, Lindsay E. Clegg, et al.. (2021). Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). SHILAP Revista de lepidopterología.1 indexed citations
Zelniker, Thomas A., Marc P. Bonaca, Remo H.M. Furtado, et al.. (2020). Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. Circulation. 141(15). 1227–1234.313 indexed citations breakdown →
Akirov, Amit, Avivit Cahn, Stefano Del Prato, et al.. (2020). Tackling obesity during the COVID‐19 pandemic. Diabetes/Metabolism Research and Reviews. 37(3). e3393–e3393.3 indexed citations
Zelniker, Thomas A., David A. Morrow, Ofri Mosenzon, et al.. (2019). Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58. Circulation.2 indexed citations
11.
Zelniker, Thomas A., Stephen D. Wiviott, Itamar Raz, et al.. (2019). Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 139(17). 2022–2031.534 indexed citations breakdown →
12.
Cahn, Avivit, Amit Akirov, & Itamar Raz. (2017). Digital therapy in diabetes. Journal of Diabetes.28 indexed citations
13.
Poulter, Neil R, Vivian Fonseca, Ofri Mosenzon, et al.. (2017). Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial. Circulation.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.